DOCSLIB.ORG

Supplementary Table 3. List of Genes Defined in the Literature As Significant in Monocyte-To-Macrophage Differentiation and Polarization

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table 3. List of Genes Defined in the Literature As Significant in Monocyte-To-Macrophage Differentiation and Polarization Supplementary Table 3. List of genes defined in the literature as significant in monocyte-to-macrophage differentiation and polarization. Entrez Reported Symbol Gene Name ID Expression Reference ADAM8 A disintegrin and metalloproteinase domain 8 101 M2 (1) ADK Adenosine kinase 132 M2 (2) AK3 Adenylate kinase 3 50808 M1 (2) ALOX15 Arachidonate 15-lipoxygenase 246 M2 (3) APOL1 Apolipoprotein L, 1 8542 M1 (2) APOL2 Apolipoprotein L, 2 23780 M1 (2) APOL3 Apolipoprotein L, 3 80833 M1 (2) APOL6 Apolipoprotein L, 6 80830 M1 (2) ARG1 Arginase, liver 383 M2 (4) ARG2 Arginase, type II 384 M2 (5) ATF3 Activating transcription factor 3 467 M1 (2) BCL2A1 BCL2-related protein A1 597 M1 (2) BID BH3 interacting domain death agonist 637 Monocyte (2) BIRC3 Baculoviral IAP repeat-containing 3 330 M1 (2) CA2 Carbonic anhydrase II 760 M2 (2) CAT Catalase 847 M2 (6) CAT2 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 6542 M2 (6) CCL1 Chemokine(C-C motif) ligand 1 6346 M2 (4) CCL11 Chemokine ligand 11, Eotaxin 6356 M1 (4) CCL13 Chemokine ligand13, MCP-4 6357 M2 (2) CCL15 Chemokine (C-C motif) ligand 15 6359 M1 (2) CCL17 Chemokine ligand17, TARC 6361 M1 & M2 (4) CCL18 Chemokine ligand 18, MIP-4 6362 M2 (4) CCL19 Chemokine ligand 19, MIP-3B 6363 M1 (2) CCL2 Chemokine ligand 2, MCP1, GDCF-2 6347 Macrophage (2) CCL20 Chemokine ligand 20, MIP-3A 6364 M1 (2) CCL22 Chemokine ligand 22, MDC 6367 M2 (7) CCL23 Chemokine (C-C motif) ligand 23 6368 M2 (2) CCL24 Chemokine ligand 24 6369 M2 (4) CCL25 Chemokine ligand 25 6370 M2 (8) CCL3 Chemokine ligand 3, MIP-1A 6348 M1 (4) CCL4 Chemokine ligand 4, MIP-1B 6351 M1 (4) CCL5 Chemokine ligand 5, RANTES 6352 M1 (4) CCL7 Chemokine ligand 7, MARC, MCP-3 6354 M2 (8) CCL8 Chemokine ligand 8, MCP-2 6355 M1 (2) CCN1 Cysteine-rich, angiogenic inducer, 61 3491 M2 (1) CCR1 Chemokine (C-C motif) receptor 1 1230 M1 & M2 (4) CCR2 Chemokine receptor 2 1231 Monocyte (4) CCR3 Chemokine receptor 3, CD193 1232 M1 & M2 (8) CCR5 Chemokine receptor 5, CD195 1234 M1 & M2 (4) CCR7 Chemokine receptor 7, CD197 1236 M1 (8) CCR9 Chemokine receptor 9 10803 M1 & M2 (8) CD115 CSF-1R 1436 M2 (8) CD11b Integrin, alpha M; Itgam 3684 M2 (1) CD11c Integrin, alpha X; Itgax 3687 M1 (8) CD14 Monocyte differentiation antigen CD14; myeloid cell-specific 929 Monocyte, M2 (9) CD16 FCGR3A, Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 2214 M1 (4) CD163 CD163 molecule 9332 M2 (10) CD204 Macrophage scavenger receptor 1, MSR1 4481 M2 (1) CD206 Mannose receptor C type 1, MRC1 4360 M2 (4) CD23A FCER2, Fc fragment of IgE, low affinity II, receptor for (CD23) 2208 M2 (3) CD28 CD28 molecule 940 Macrophage (2) CD36 Leukocyte differentiation antigen 948 M2 (2) CD44 CD44 molecule 960 Macrophage (11) CD47 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) 961 M1 (3) CD68 CD68 molecule 968 M1 & M2 (7) CD74 CD74 molecule, Major histocompatibility complex, class II invariant chain 972 M1 (7) CD80 CD28LG, B-lymphocyte activation antigen B7 941 M1 (7) CD83 CD83 molecule 9308 Monocyte (2) CD86 CD86 molecule, CD28LG2 942 M1 (7) CDA Cytidine deaminase 978 Macrophage (2) CDC2 Cell division cycle 2, G1 to S and G2 to M 983 Macrophage (2) CDC20 Cell division cycle 20 homolog (S. cerevisiae) 991 Macrophage (2) CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 999 M2 (3) CDKN1C Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 1028 Monocyte (2) CDKN3 Cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) 1033 M1 (2) CERK Ceramide kinase 64781 M2 (2) CHI3L2 Chitinase 3-like 2 1117 M1 (2) CHN2 Chimerin (chimaerin) 2 1124 M2 (2) CLEC7A C-type lectin domain family 7, member A; Dectin 1 64581 M2 (2) CLECSF13 CLEC4F, C-type lectin domain family 4, member F 165530 M2 (2) CRLF2 Cytokine receptor-like factor 2 64109 M1 (12) CSF-1 Colony stimulating factor 1 (MF), MCSF 1435 M2 (1) CSF-2 Colony stimulating factor 2 (granulocyte-macrophage), GMCSF 1437 M1 (2) CSPG2 VCAN, versican 1462 M1 (2) CTSB Cathepsin B 1508 M1 & M2 (1) CTSC Cathepsin C 1075 M2 (2) CX3CR1 Chemokine (C-X3-C motif) receptor 1 1524 Monocyte (4) CXCL1 Chemokine (C-X-C motif) ligand 1 2919 M1 (4) CXCL10 Chemokine ligand 10, IP-10 3627 M1 (4) CXCL11 Chemokine (C-X-C motif) ligand 11 6373 M1 (9) CXCL16 Chemokine ligand 16 58191 M1 (9) CXCL2 Chemokine ligand 2 2920 M1 (4) CXCL3 Chemokine (C-X-C motif) ligand 3 2921 M1 (4) CXCL5 Chemokine ligand 5, ENA-78 6374 M1 (4) CXCL8/IL-8 C-X-C motif chemokine 8, T-cell chemotactic factor; beta-thromboglobulin-like protein 3576 M1 (4) CXCL9 Chemokine ligand 9 4283 M1 (2) CXCR1 Chemokine (C-X-C motif) receptor 1 3577 M2 (9) CXCR2 Chemokine receptor 2, CD182, IL8RA 3579 M2 (9) CXCR4 Chemokine receptor 4, CD184 7852 M2 (4) DCL-1 CD302 molecule 9936 M2 (2) DCSIGN CD209 molecule 30835 M2 (2) DC-STAMP Domain containing 2, Hypothetical protein FLJ32934 127579 M2 (13) DHCR24 24-dehydrocholesterol reductase 1718 M2 (14) ECGF1 Endothelial cell growth factor 1 (platelet-derived) 1890 M1 (2) EDN1 Endothelin 1 1906 M1 (2) EGF Epidermal growth factor 1950 M2 (1) EGR1 Early growth response 1 1958 Macrophage (15) EGR2 Early growth response 2 (Krox-20 homolog, Drosophila) 1959 M2 (2) EMR2 Egf-like module containing, mucin-like, hormone receptor-like 2; CD312 30817 M1 & M2 (7) Zinc finger protein 808, EMR1, Egf-like module containing, mucin-like, hormone F4/80 receptor-like 1 2015 Macrophage (1) FAS Fas (TNF receptor superfamily, member 6) 355 M1 (2) FGL2 Fibrinogen-like 2, fibroleukin 10875 M2 (2) FN1 Fibronectin 1, Zinc finger protein 706 2335 M2 (3) FXIIIA1 F8, coagulation factor VIII, procoagulant component 2157 M2 (3) GADD45G Growth arrest and DNA-damage-inducible, gamma 10912 M1 (2) GAS6 Growth arrest-specific 6 2621 M2 (3) GAS7 Growth arrest-specific 7 8522 M2 (2) GM-CSFR Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 1439 M1 (16) GPR86 Purinergic receptor P2Y, G-protein coupled 53829 M2 (2) HESX1 HESX homeobox 1 8820 M1 (2) HEXB Hexosaminidase B (beta polypeptide) 3074 M2 (2) HK3 Hexokinase 3 (white cell) 3101 Macrophage (2) HLA-DPA1 Major histocompatibility complex, class II, DP alpha 1 3113 Monocyte (2) HLA-DPB1 Major histocompatibility complex, class II, DP beta 1 3115 Monocyte (2) HLA-DQA1 Major histocompatibility complex, class II, DQ alpha 1 3117 Monocyte (2) HLA-DQB1 Major histocompatibility complex, class II, DQ beta 1 3119 Monocyte (2) HLA-DQB2 Major histocompatibility complex, class II, DQ beta 2 3120 Monocyte (2) HLA-DQB3 Major histocompatibility complex, class II, DQ beta 3 3121 Monocyte (2) HLA-DRA Major histocompatibility complex, class II, DR alpha 3122 Monocyte (2) HLA-DRB1 Major histocompatibility complex, class II, DR beta 1 3123 Monocyte (2) HLA-DRB2 Major histocompatibility complex, class II, DR beta 2 (pseudogene) 3124 Monocyte (2) HLA-DRB4 Major histocompatibility complex, class II, DR beta 4 3126 Monocyte (2) HLA-E Major histocompatibility complex, class I, E 3133 Monocyte (2) HNMT Histamine N-methyltransferase 3176 M2 (2) HRH1 Histamine receptor H1 3269 M2 (2) HS3ST1 Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 9957 M2 (2) HS3ST2 Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 9956 M2 (2) HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 3290 M1 (2) HSXIAPAF1 XIAP associated factor 1 54739 M1 (2) IFN-g Interferon, gamma 3458 M1 (17) IGF1 Insulin-like growth factor 1 (somatomedin C) 3479 M2 (2) IGFBP4 Insulin-like growth factor binding protein 4 3487 M1 (2) IL-1 Interleukin 1, alpha; IL-1A 3552 M1 (4) IL-10 Interleukin 10A 3586 M1 (4) IL10RA Interleukin 10 receptor, alpha 3587 Monocyte (2) IL-12 Interleukin 12A, p35 3592 M1 (4) IL12B Interleukin 12B (cytotoxic lymphocyte maturation factor 2, p40) 3593 M1 (2) IL-13 Interleukin 13 3596 M2 (18) IL-13RA1 Interleukin 13 receptor, alpha 1 3597 M2 (3) IL-13RA2 Interleukin 13 receptor, alpha 2 3598 M2 (3) IL15 Interleukin 15 3600 M1 (2) IL15RA Interleukin 15 receptor, alpha 3601 M1 (2) IL-17 Interleukin 17A, cytotoxic T-lymphocyte-associated antigen 8 3605 M2 (3) IL-18 Interleukin 18 3606 M2 (1) IL-1b Interleukin 1, beta; IL1F2 3553 M1 & M2 (8) IL-1RA Interleukin 1 receptor antagonist 3557 M2 (4) IL1RL1 Interleukin 1 receptor-like 1, ST2 9173 M2 (19) IL-2 Interleukin 2 3558 M1 (20) IL-21 Interleukin 21 59067 M2 (21) IL-21R Interleukin 21 receptor 50615 M2 (22) IL-23 Interleukin 23, alpha; P19 51561 M1 (9) IL-27RA Interleukin 27 receptor, alpha 9466 M2 (13) IL2RA Interleukin 2 receptor, alpha 3559 M1 (2) IL-33 Interleukin 33 90865 M2 (19) IL-4 Interleukin 4 3565 M2 (3) IL-4RA Interleukin 4 receptor subunit alpha 3566 M2 (3) IL-6 Interleukin 6 (interferon, beta 2), HGF 3569 M1 (4) IL-7R Interleukin 7 receptor, CD127 3575 M1 (2) INDO Indoleamine 2,3-dioxygenase 1 3620 M1 (2) INHBA Inhibin, beta A 3624 M1 (2) iNOS Nitric oxide synthase 2, inducible; NOS2A 4843 M1 (8) IRF1 Interferon regulatory factor 1 3659 M1 (2) IRF4 Interferon regulatory factor 4 3662 M2 (23) IRF7 Interferon regulatory factor 7 3665 M1 (2) IRF8 Interferon regulatory factor 8 3394 M1 (24) LILRB4 Leukocyte immunoglobulin-like receptor, subfamily B, member 4 11006 Monocyte (2) LIPA Lipase A, lysosomal acid, cholesterol esterase 3988 M2 (2) LTA4H Leukotriene A4 hydrolase 4048 M2 (2) LYN V-yes-1 Yamaguchi sarcoma viral related oncogene homolog 4067 M2 (1) MAF v-Maf musculoaponeurotic fibrosarcoma oncogene homolog 4094 M2 (2) MAO-A Monoamine oxidase A 4128 M2 (3) MARCO Macrophage receptor with collagenous structure 8685 M1 (25) MMP12 Macrophage metalloelastase, matrix metallopeptidase 12 (macrophage elastase) 4321 M1 & M2 (26) MMP14
Load more

Recommended publications
  • Serum Scd163 As a Biomarker of Adipose Tissue Inflammation in Obstructive Sleep Apnoea Patients: Limits and Perspectives
    AGORA | CORRESPONDENCE Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives To the Editor: Recently, MURPHY et al. [1] demonstrated, through a challenging animal, cellular and human translational approach, that intermittent hypoxia induces a pro-inflammatory activation of adipose tissue macrophages (ATMs), promoting insulin resistance. They confirmed that intermittent hypoxia lowers insulin-mediated glucose uptake in 3T3-L1 adipocytes, and evidenced the interrelationship between inflammation and insulin resistance in the adipose tissue of mice exposed to intermittent hypoxia. They then measured the concentration of serum soluble CD163 (sCD163), an assumed pro-inflammatory biomarker reflecting macrophage activation, in obstructive sleep apnoea (OSA) patients classified according to their BMI and apnoea/hypopnoea index (AHI). This is the first time serum sCD163 has been evaluated in OSA patients, and its association with AHI is promising. With the aim of enhancing its relevance in further studies, we wish to discuss the following points. 1) Activation of adipose tissue macrophages (ATMs) towards M1 phenotype in OSA patients. MURPHY et al. [1] made the assumption that circulating sCD163 levels in OSA patients reflect the intermittent hypoxia-dependent polarisation of ATMs towards a M1 phenotype. As appropriately cited, KRAČMEROVÁ et al. [2] showed that circulating sCD163 concentrations are associated with both macrophage content in human adipose tissue, and insulin sensitivity. However, the assumption that serum sCD163 reflects such a polarisation based on the ADAM-17-dependent cleavage, as hypothesised by ETZERODT et al. [3], is unconvincing since only shown in HEK293 cells. Human ATMs are characterised by a high expression of CD163 which, in contrast, is weakly expressed in differentiated M1 macrophages [4].
    [Show full text]
  • PARSANA-DISSERTATION-2020.Pdf
    DECIPHERING TRANSCRIPTIONAL PATTERNS OF GENE REGULATION: A COMPUTATIONAL APPROACH by Princy Parsana A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2020 © 2020 Princy Parsana All rights reserved Abstract With rapid advancements in sequencing technology, we now have the ability to sequence the entire human genome, and to quantify expression of tens of thousands of genes from hundreds of individuals. This provides an extraordinary opportunity to learn phenotype relevant genomic patterns that can improve our understanding of molecular and cellular processes underlying a trait. The high dimensional nature of genomic data presents a range of computational and statistical challenges. This dissertation presents a compilation of projects that were driven by the motivation to efficiently capture gene regulatory patterns in the human transcriptome, while addressing statistical and computational challenges that accompany this data. We attempt to address two major difficulties in this domain: a) artifacts and noise in transcriptomic data, andb) limited statistical power. First, we present our work on investigating the effect of artifactual variation in gene expression data and its impact on trans-eQTL discovery. Here we performed an in-depth analysis of diverse pre-recorded covariates and latent confounders to understand their contribution to heterogeneity in gene expression measurements. Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from the Genotype Tissue Expression (GTEx) project. Finally, we characterized two trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid. Second, we present a principal component based residualization method to correct gene expression measurements prior to reconstruction of co-expression networks.
    [Show full text]
  • Gene Expression Polarization
    Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression This information is current as of September 27, 2021. Fernando O. Martinez, Siamon Gordon, Massimo Locati and Alberto Mantovani J Immunol 2006; 177:7303-7311; ; doi: 10.4049/jimmunol.177.10.7303 http://www.jimmunol.org/content/177/10/7303 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2006/11/03/177.10.7303.DC1 Material http://www.jimmunol.org/ References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/177/10/7303.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 Fernando O.
    [Show full text]
  • Cellular and Plasma Proteomic Determinants of COVID-19 and Non-COVID-19 Pulmonary Diseases Relative to Healthy Aging
    RESOURCE https://doi.org/10.1038/s43587-021-00067-x Cellular and plasma proteomic determinants of COVID-19 and non-COVID-19 pulmonary diseases relative to healthy aging Laura Arthur1,8, Ekaterina Esaulova 1,8, Denis A. Mogilenko 1, Petr Tsurinov1,2, Samantha Burdess1, Anwesha Laha1, Rachel Presti 3, Brian Goetz4, Mark A. Watson1, Charles W. Goss5, Christina A. Gurnett6, Philip A. Mudd 7, Courtney Beers4, Jane A. O’Halloran3 and Maxim N. Artyomov1 ✉ We examine the cellular and soluble determinants of coronavirus disease 2019 (COVID-19) relative to aging by performing mass cytometry in parallel with clinical blood testing and plasma proteomic profiling of ~4,700 proteins from 71 individuals with pul- monary disease and 148 healthy donors (25–80 years old). Distinct cell populations were associated with age (GZMK+CD8+ T cells and CD25low CD4+ T cells) and with COVID-19 (TBET−EOMES− CD4+ T cells, HLA-DR+CD38+ CD8+ T cells and CD27+CD38+ B cells). A unique population of TBET+EOMES+ CD4+ T cells was associated with individuals with COVID-19 who experienced moderate, rather than severe or lethal, disease. Disease severity correlated with blood creatinine and urea nitrogen levels. Proteomics revealed a major impact of age on the disease-associated plasma signatures and highlighted the divergent contri- bution of hepatocyte and muscle secretomes to COVID-19 plasma proteins. Aging plasma was enriched in matrisome proteins and heart/aorta smooth muscle cell-specific proteins. These findings reveal age-specific and disease-specific changes associ- ated with COVID-19, and potential soluble mediators of the physiological impact of COVID-19.
    [Show full text]
  • Anti-OX40 Antibody Directly Enhances the Function of Tumor-Reactive CD8+ T Cells
    Author Manuscript Published OnlineFirst on August 1, 2019; DOI: 10.1158/1078-0432.CCR-19-1259 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma Weiyi Peng1,5*, Leila J. Williams1, Chunyu Xu1,5, Brenda Melendez1, Jodi A. McKenzie1,6, Yuan Chen1, Heather Jackson2, Kui S. Voo3, Rina M. Mbofung1,7,, Sara E. Leahey1, Jian Wang4, Greg Lizee1, Hussein A. Tawbi1, Michael A. Davies1, Axel Hoos2, James Smothers2, Roopa Srinivasan2, Elaine Paul2, Niranjan Yanamandra2* and Patrick Hwu1* 1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 2Oncology R&D, Immuno-Oncology and Combinations RU, GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, PA 19426, United States 3Oncology Research for Biologics and Immunotherapy Translation Platform, The University of Texas MD Anderson Cancer Center, Houston, TX. 4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 5Present address: Department of Biology and Biochemistry, University of Houston, Houston, TX. 6Present address: Eisai Inc., Woodcliff Lake, NJ. 7Present address: Merck Research Laboratories, Palo Alto, CA. Running Title: OX40 agonist-based cancer immunotherapy Keywords: OX40, PI3K, cancer immunotherapy Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 1, 2019; DOI: 10.1158/1078-0432.CCR-19-1259 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 2 *Corresponding Authors: Patrick Hwu, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
    [Show full text]
  • Molecular Signatures of G-Protein-Coupled Receptors A
    REVIEW doi:10.1038/nature11896 Molecular signatures of G-protein-coupled receptors A. J. Venkatakrishnan1, Xavier Deupi2, Guillaume Lebon1,3,4,5, Christopher G. Tate1, Gebhard F. Schertler2,6 & M. Madan Babu1 G-protein-coupled receptors (GPCRs) are physiologically important membrane proteins that sense signalling molecules such as hormones and neurotransmitters, and are the targets of several prescribed drugs. Recent exciting developments are providing unprecedented insights into the structure and function of several medically important GPCRs. Here, through a systematic analysis of high-resolution GPCR structures, we uncover a conserved network of non-covalent contacts that defines the GPCR fold. Furthermore, our comparative analysis reveals characteristic features of ligand binding and conformational changes during receptor activation. A holistic understanding that integrates molecular and systems biology of GPCRs holds promise for new therapeutics and personalized medicine. ignal transduction is a fundamental biological process that is comprehensively, and in the process expand the current frontiers of required to maintain cellular homeostasis and to ensure coordi- GPCR biology. S nated cellular activity in all organisms. Membrane proteins at the In this analysis, we objectively compare known structures and reveal cell surface serve as the communication interface between the cell’s key similarities and differences among diverse GPCRs. We identify a external and internal environments. One of the largest and most diverse consensus structural scaffold of GPCRs that is constituted by a network membrane protein families is the GPCRs, which are encoded by more of non-covalent contacts between residues on the transmembrane (TM) than 800 genes in the human genome1. GPCRs function by detecting a helices.
    [Show full text]
  • CD74 Targeted Nanoparticles As Dexamethasone Delivery System for B Lymphoid Malignancies
    CD74 targeted nanoparticles as Dexamethasone Delivery System for B lymphoid malignancies DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Georgia Triantafillou, MPH Integrated Biomedical Sciences Graduate Program The Ohio State University 2011 Dissertation Committee John C. Byrd, MD, advisor Natarajan Muthusamy, PhD co-advisor Robert J.Lee, PhD, co-advisor Mitch A.Phelps, PhD, co-advisor Guido Marcucci, MD committee member Susheela Tridandapani, PhD committee member Copyright page Georgia Triantafillou 2011 ABSTRACT Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is not curable with standard therapy. In CLL the B lymphocytes appear morphologically mature but immunologically express less mature B cell makers. Specifically, the CLL B cells co-express surface antigens including CD19, CD20, CD5, CD23. Due to nonspecific delivery of the drugs to malignant as well as normal cells, patients experience numerous side effects. Targeted drug delivery to cancer cells is a desirable goal for all anti cancer strategies. Corticosteroids have been proven to be a beneficial and well established part of CLL treatment. Dexamethasone(DEX) is frequently used in CLL therapies as well as other malignancies and antiinflammatory diseases. However, DEX nonspecifically enters all tissues inducing various toxicities to patients. Therefore, DEX treatment is often discontinued or not administered to certain patients. We aimed to deliver this efficient clinical agent via a targeted delivery vehicle and examine its effect on its target B-CLL cells. The main scope of the work presented is the creation of a sterically stable nanoparticle, an ii immunoliposome (ILP), that has DEX encapsulated in its interior and a monoclonal antibody(Mab) in its exterior targeting CLL B cells expressing the surface antigen that is recognized by the Mab.
    [Show full text]
  • Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3
    RX Zhang, et al ORIGINAL ARTICLE Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3 1 Department of Otolaryngology, Huadong Hospital, Fudan University, Shanghai, China 2 Department of Otolaryngology , Jinan General Hospital of PLA, Shandong, China 3 Department of Otolaryngology, Changhai Hospital, Second Military Medical University, Shanghai, China ■ Abstract Objective: To analyze the roles of chemokines and their receptors in the pathogenesis of allergic rhinitis by observing the complementary DNA (cDNA) expression of the chemokines and their receptors in the nasal mucosa of patients with and without allergic rhinitis, using gene chips. Methods: The total RNAs were isolated from the nasal mucosa of 20 allergic rhinitis patients and purifi ed to messenger RNAs, and then reversely transcribed to cDNAs and incorporated with samples of fl uorescence-labeled with Cy5-dUPT (rhinitis patient samples) or Cy3- dUTP (control samples of nonallergic nasal mucosa). Thirty-nine cDNAs of chemokines and their receptors were latticed into expression profi le chips, which were hybridized with probes and then scanned with the computer to study gene expression according to the different fl uorescence intensities. Results: The cDNAs of the following chemokines were upregulated: CCL1, CCL2, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL24, and CX3CL1 in most of the allergic rhinitis sample chips. CCR2, CCR3, CCR4, CCR5, CCR8 and CX3CR1 were the highly expressed receptor genes. Low expression of CXCL4 was found in these tissues. Conclusion: The T helper cell (TH) immune system is not well regulated in allergic rhinitis.
    [Show full text]
  • Anti-CCL13 / MCP4 Antibody (Biotin) (ARG65993)
    Product datasheet [email protected] ARG65993 Package: 50 μg anti-CCL13 / MCP4 antibody (Biotin) Store at: 4°C Summary Product Description Biotin-conjugated Goat Polyclonal antibody recognizes CCL13 / MCP4 Tested Reactivity Hu Tested Application ELISA, WB Host Goat Clonality Polyclonal Isotype IgG Target Name CCL13 / MCP4 Antigen Species Human Immunogen E. coli derived recombinant Human CCL13 / MCP4. (QPDALNVPST CCFTFSSKKI SLQRLKSYVI TTSRCPQKAV IFRTKLGKEI CADPKEKWVQ NYMKHLGRKA HTLKT) Conjugation Biotin Alternate Names SCYA13; C-C motif chemokine 13; Monocyte chemotactic protein 4; Small-inducible cytokine A13; CKb10; SCYL1; Monocyte chemoattractant protein 4; MCP-4; NCC-1; NCC1; CK-beta-10 Application Instructions Application table Application Dilution ELISA Direct: 0.25 - 1.0 µg/ml Sandwich: 0.25 - 1.0 µg/ml with ARG65992 as a capture antibody WB 0.1 - 0.2 µg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 11 kDa Properties Form Liquid Purification Purified by affinity chromatography. Buffer PBS (pH 7.2) Concentration 1 mg/ml Storage instruction Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Database links GeneID: 6357 Human Swiss-port # Q99616 Human Gene Symbol CCL13 Gene Full Name chemokine (C-C motif) ligand 13 Background This antimicrobial gene is one of several Cys-Cys (CC) cytokine genes clustered on the q-arm of chromosome 17.
    [Show full text]
  • Single-Cell RNA Sequencing Identifies Candidate Renal
    BASIC RESEARCH www.jasn.org Single-Cell RNA Sequencing Identifies Candidate Renal Resident Macrophage Gene Expression Signatures across Species Kurt A. Zimmerman,1 Melissa R. Bentley,1 Jeremie M. Lever ,2 Zhang Li,1 David K. Crossman,3 Cheng Jack Song,1 Shanrun Liu,4 Michael R. Crowley,3 James F. George,5 Michal Mrug,2,6 and Bradley K. Yoder1 1Department of Cell, Developmental, and Integrative Biology, 2Division of Nephrology, Department of Medicine, 3Department of Genetics, 4Department of Biochemistry and Molecular Genetics, and 5Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama; and 6Department of Veterans Affairs Medical Center, Birmingham, Alabama ABSTRACT Background Resident macrophages regulate homeostatic and disease processes in multiple tissues, in- cluding the kidney. Despite having well defined markers to identify these cells in mice, technical limita- tions have prevented identification of a similar cell type across species. The inability to identify resident macrophage populations across species hinders the translation of data obtained from animal model to human patients. Methods As an entry point to determine novel markers that could identify resident macrophages across species, we performed single-cell RNA sequencing (scRNAseq) analysis of all T and B cell–negative CD45+ innate immune cells in mouse, rat, pig, and human kidney tissue. Results We identified genes with enriched expression in mouse renal resident macrophages that were also present in candidate resident macrophage populations across species. Using the scRNAseq data, we defined a novel set of possible cell surface markers (Cd74 and Cd81) for these candidate kidney resident macrophages. We confirmed, using parabiosis and flow cytometry, that these proteins are indeed enriched in mouse resident macrophages.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • General Discussion
    UvA-DARE (Digital Academic Repository) EGF-TM7 receptors: A diverse and still evolving family of receptors on the leukocyte surface Matmati, M. Publication date 2008 Link to publication Citation for published version (APA): Matmati, M. (2008). EGF-TM7 receptors: A diverse and still evolving family of receptors on the leukocyte surface. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:23 Sep 2021 Chapter 6 General Discussion GENERAL DISCUSSION Since their identification, starting about 15 years ago, a growing amount of data has accumulated about the structure, the expression, the ligands and, more recently, also the functional implications of EGF-TM7 receptors. Studies with antibody treatment and gene targeting in mice and antibody treatment of human cells in vitro, led to the implication of EGF-TM7 receptors in the trafficking of granulocytes, the generation of efferent antigen specific regulatory T cells and the potentiation of different granulocyte effector functions [1-4].
    [Show full text]